Comparison · NCT04649151-09a40bc0
Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With a First Occurrence of Symptomatic COVID-19
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Part 1A: mRNA-1273 100 μg vs Part 1A: Placebo: Part 1A Number of Participants With a First Occurrence of Symptomatic COVID-19. Trial comparisons, record NCT04649151-09a40bc0. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT04649151-09a40bc0
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0 | 0 | 0.00179 | wilson | |
| Risk in group 2 | 0.00575 | 0.00264 | 0.0125 | wilson | |
| Risk difference, group 1 minus group 2 | -0.00575 | -0.0125 | -0.00216 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | log | a group has no participants with the outcome | |||
| Odds ratio, group 1 over group 2 | log | a cell of the two-by-two table is zero | |||
| Number needed to treat, for one fewer participant with the outcome on Part 1A: mRNA-1273 100 μg than on Part 1A: Placebo | 174 | 80.1 | 463 | from the risk difference interval |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Part 1A: mRNA-1273 100 μg | Participants received at least 1 of 2 doses of 100 μg mRNA-1273 by IM injection (Day 1 and Day 29). | 0 | 2,142 | OG000 |
| Group 2 | Part 1A: Placebo | Participants received at least 1 of 2 doses of placebo matched to mRNA-1273 100 μg by IM injection (Day 1 and Day 29). | 6 | 1,044 | OG001 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Part 1A Number of Participants With a First Occurrence of Symptomatic COVID-19
- Description
COVID-19 was defined as symptomatic disease based on the following criteria: participants experienced at least 2 of the following systemic symptoms: fever (≥ 38ºC/≥ 100.4ºF), chills, myalgia, headache, sore throat, new olfactory and taste disorder(s); or experienced at least 1 of the following respiratory signs/symptoms: cough, shortness of breath or difficulty breathing, or clinical or radiographical evidence of pneumonia; and had at least 1 nasopharyngeal swab, nasal swab, or saliva sample (or respiratory sample, if hospitalized) positive for SARS-CoV-2.
- Time frame
- Day 43 (14 days after second injection) up to 2.5 months after second injection
- Population
Part 1A PP Set for Efficacy: all randomized participants who received planned doses of study drug, had no immunologic or virologic evidence of prior COVID-19, and had no major protocol deviations that impact key or critical efficacy data.
Source ClinicalTrials.gov
Trial
- Title
- A Study to Evaluate the Safety, Reactogenicity, and Effectiveness of mRNA-1273 Vaccine in Adolescents 12 to <18 Years Old to Prevent COVID-19
- NCT number
- NCT04649151
- Phases
- PHASE2, PHASE3
- Conditions
- SARS-CoV-2
- Interventions
- mRNA-1273, Placebo, mRNA-1273.222
- Lead sponsor
- ModernaTX, Inc.
- Results first posted
- 2025-09-15
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT04649151?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT04649151-09a40bc0